The International Standards for Cytogenomic Arrays consortium has changed its name to reflect new collaborations with laboratories that rely mainly on next-generation sequencing, as well as with clinical geneticists for whom data interpretation and counseling, rather than technol
The addition of SNP content will further enable cytogeneticists using Agilent arrays to detect constitutional abnormalities, and could help make Agilent more competitive against firms like Affymetrix and Illumina that currently sell SNP platforms for cytogenetic research.
The International Standard Cytogenomic Array Consortium said chromosomal microarrays should replace G-banded karyotypes as the first-tier technology to test individuals with unexplained developmental delay and certain intellectual disabilities.
Spencer Howell, director of cytogenetics at OGT, said this week that the Oxford, UK-based firm is seeing "massive uptake" in the cytogenetics market, and that customers "prefer a standard design" over other designs available today.
There was evidence at the conference that SNP and CGH arrays have made considerable inroads into the cytogenetics market over the past few years, but a number of talks addressed issues that clinicians face as they look to bring arrays into their practice.